IRCT20200324046850N2已完成2 期
Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19 Patients with Severe Symptoms
Abadan University of Medical Sciences0 个研究点目标入组 62 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •COVID-19 patients that have positive PCR test of nasopharyngeal sample or have bilateral multi-lobar ground glass opacity in CT scan
- •O2 saturation under 94% or respiratory rate above 24 or decreased level of consciousness
排除标准
- •patients under 18 years
- •pregnant or breast feeding women
- •patients did not consent to participate in the study
- •patients who took any complementary medicine
- •safety problem for patients
- •patients with any allergy or hypersensitivity to Sofosbuvir + Daclatasvir or Ribavirin or with major interaction with other medicine
研究者
相似试验
已完成
3 期
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19IRCT20200624047908N1Abadan University of Medical Sciences1,000
已完成
不适用
Safety And Effectiveness Of Sofosbuvir And Daclatasvir In Patients Who Have Thalassemia With Hepatitis C Virus Infection And Who Are 6 years To 18 Years OldCTRI/2020/06/025910Riten Kumar Samadder70
已完成
3 期
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCVIRCT20080901001155N30Rasht University of Medical Sciences16
已完成
不适用
Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysis.IRCT20170614034526N3Jinnah Hospital, Lahore36
尚未招募
Unknown
Investigating the in vivo bioequivalence of Sofosbuvir/Daclatasvir tabletIn the present study, the products will be administered to healthy volunteers..IRCT20220211053992N8Tabriz University of Medical Sciences24